vimarsana.com

Latest Breaking News On - Laidlaw company - Page 6 : vimarsana.com

Algorithm Sciences, a Laidlaw Venture Partners Portfolio

Ionis Pharmaceuticals, inc (IONS) Q2 2021 Earnings Call Transcript

Ionis Pharmaceuticals, inc (IONS) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

Laidlaw Venture Partners Portfolio Company Algorithm Sciences, Inc Closes $5 0 Million Series B Financing Round

Laidlaw Venture Partners Portfolio Company Algorithm Sciences, Inc. Closes $5.0 Million Series B Financing Round NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $5.0 million Series B financing round for its portfolio company Algorithm Sciences, Inc. Algorithm Sciences is a development stage biopharmaceutical company focused on optimizing treatment for rare cardiovascular diseases (CVDs). Despite the fact that many drugs have been approved for treatment of various CVDs, it is recognized in the medical community that treatment could be significantly improved. Through the company’s lead product, we believe Algorithm Sciences has the tools and technologies to deliver therapy to achieve improved outcomes.

BioSig Technologies Inc looking to unlock the future of bioelectronic medicine

BioSig Technologies Inc looking to unlock the future of bioelectronic medicine
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

UPDATE – Laidlaw Venture Partners Portfolio Company AerWave Medical, Inc Closes $4 Million Series A Financing Round

Share: NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) Laidlaw Venture Partners ( LVP ), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $4 million Series A financing round for its portfolio company AerWave. AerWave offers an interventional approach to treat Asthma, COPD and advanced lung disease, which addresses a significant unmet medical need. It is targeting the addressable COPD market made up of 4 million patients in the US, and the addressable Asthma market of 2.5 million patients in the US. The Company has broad intellectual property protection in place and a seasoned, experienced executive team with a track record of value creation.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.